[1] Li X, Ye F, Chen H, et al. Human ovaria carcinoma cells generates CD4(+) CD25(+) regulatory T cell from peripheral CD4 (+) CD25 (-) T cell through secreting TGF-beta[J].Cancer Letter,2007, 253(1):144-153. [2] Kim ES, Kim M S, Mo on A. Transforming growth factor(TGF-beta) in conjunction with H-ras activation promotes malignant progression of MCF10A breast epithelial cells[J].Cytokine, 2005, 29(2):84-91. [3] Andersson A, Yang SC, Huang M, et al.IL-7 promotes CXCR3 ligand-dependt T cell antitumor reactiveity in lung cancer[J].J Immunol, 2009, 182(11):6951-6958. [4] 谢强, 蒋志文, 祝晓光, 等.HSPG 和无H S-GAGs链HSPG 体外抗乳腺癌的研究[J].中国临床药理学与治疗学, 2009, 14(6):617-623. [5] Lynch DH, Miller RE. Interleukin 7 promotes long term in vitro groth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo[J].J Exp Med, 1994, 179:32-42. [6] Geiselhart LA, Humphries CA, Gregorio TA, et al.IL-7 administration alters the CD4:CD8 ratio, increase T cell number, and increase Tcell function in the absence of activation[J].J Immunol, 2001, 166(5):3019-3027. [7] Krawczenko A, Kieda C, Dus D. The bio log ical role and potential therapeutic application of IL-7[J].Arch Immunol Ther Exp, 2005, 53(6):518-525. [8] Lezzi G, Pia ttelli A, Rubini C, et al. Expression of transforming growth factor beta1 in a ameloblastomas[J].J C raniofac Surg, 2008, 19(6):1618-1621. [9] Yanagaw a Y, Iwabuchi K, Onoé K. Co-o perative action of interleukin-10 and inter feron-gama to regulate dendritic cell function[J].Immunology, 2009,127(3):345-353. [10] Chung EK, Stadler WM. Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer[J].Clin Genitourin Cancer, 2008, 6(1):S22-S28. |